Advanced Accelerator Applications
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$96.8M
Doctors Paid
1,188
Transactions
2,906
2024 Total
$63.9M
Payment Breakdown by Category
Research$2.4M (2.4%)
Consulting$486,299 (0.5%)
Travel$83,417 (0.1%)
Food & Beverage$61,613 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $93.7M | 745 | 96.7% |
| Unspecified | $2.4M | 202 | 2.4% |
| Consulting Fee | $486,299 | 176 | 0.5% |
| Travel and Lodging | $83,417 | 191 | 0.1% |
| Honoraria | $78,667 | 26 | 0.1% |
| Grant | $64,750 | 12 | 0.1% |
| Food and Beverage | $61,613 | 1,473 | 0.1% |
| Space rental or facility fees (teaching hospital only) | $10,800 | 5 | 0.0% |
| Education | $8,824 | 76 | 0.0% |
Payments by Type
General
$94.5M
2,704 transactions
Research
$2.4M
202 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer | $860,396 | 0 | 2 |
| A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours | $534,333 | 1 | 77 |
| PROter study | $222,121 | 0 | 17 |
| Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (NETTER-2) | $148,876 | 0 | 2 |
| Netter 1 | $98,739 | 0 | 46 |
| Annexin-03 / Annexin-04 / Annexin-05 | $86,092 | 1 | 6 |
| DOSIMETRY GUIDED PRRT WITH 177LU-DOTATATE IN CHILDREN AND ADOLESCENTS | $69,725 | 0 | 1 |
| NEORAY | $66,427 | 0 | 3 |
| NeoRay | $61,435 | 0 | 2 |
| Annexin | $43,467 | 0 | 1 |
| NETTER-1 CLINICAL TRIAL | $42,214 | 0 | 14 |
| STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LUTATHERA IN PATIENTS WITH GRADE 2 AND GRADE 3 ADVANCED | $32,520 | 0 | 5 |
| Somatostatin Receptor Expression in Poorly-differentiated neuroendocrine carcinomas of the GI Tract: analysis using Ga-dotatate PET scan | $24,799 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2021 |
|---|---|---|---|---|
| Michael Morse, M.d, M.D | Hematology & Oncology | Durham, NC | $66,871 | $0 |
| Eric Liu, M.d, M.D | Surgical Oncology | Denver, CO | $64,099 | $0 |
| Jonathan Strosberg, Md, MD | Medical Oncology | Tampa, FL | $42,586 | $0 |
| Giuseppe Esposito, Md, MD | Nuclear Imaging & Therapy | Washington, DC | $39,368 | $0 |
| Dr. Mary Hobbs Maluccio, Md, Mph, MD, MPH | Surgical Oncology | Metairie, LA | $33,055 | $0 |
| Dr. Daneng Li, M.d, M.D | Internal Medicine | Duarte, CA | $32,180 | $0 |
| Samuel Mehr | Diagnostic Radiology | Omaha, NE | $31,553 | $0 |
| Dr. Robert Ramirez, D.o, D.O | Internal Medicine | Nashville, TN | $30,853 | $0 |
| Dr. Hagen Kennecke, Md, Mha, Frcpc, MD, MHA, FRCPC | Hematology & Oncology | Portland, OR | $29,413 | $0 |
| Dr. Neal Shore, Dr, DR | Urology | Myrtle Beach, SC | $27,219 | $0 |
| Evan Yu | Medical Oncology | Seattle, WA | $26,287 | $0 |
| Dr. Alton Sartor, M.d, M.D | Medical Oncology | Rochester, MN | $23,725 | $0 |
| Phillip Koo, Md, MD | Diagnostic Radiology | Aurora, CO | $19,159 | $0 |
| Dr. Thomas Schindler, Md, MD | Cardiovascular Disease | Saint Louis, MO | $18,200 | $0 |
| Dr. Salvador Borges-Neto, M.d, M.D | Nuclear Medicine | Durham, NC | $17,507 | $0 |
| Dr. Andrew Hendifar, Md, Mph, MD, MPH | Internal Medicine | West Hollywood, CA | $15,586 | $0 |
| Dr. Pamela Kunz, M.d, M.D | Medical Oncology | New Haven, CT | $14,674 | $0 |
| Daniel George, M.d, M.D | Urology | Durham, NC | $14,228 | $0 |
| Vivek Mehta, M.d, M.D | Radiation Oncology | Seattle, WA | $14,133 | $0 |
| Dr. Alicia Morgans, Md, MD | Medical Oncology | Boston, MA | $14,000 | $0 |
| Daniel Halperin, Md, MD | Medical Oncology | Houston, TX | $13,818 | $0 |
| Dr. Diane Reidy-Lagunes, Md, Ms, MD, MS | Hematology & Oncology | New York, NY | $13,120 | $0 |
| Ulka Vaishampayan, Md, MD | Medical Oncology | Ann Arbor, MI | $12,519 | $0 |
| Nicholas Vogelzang, Md, MD | Hematology & Oncology | Las Vegas, NV | $11,993 | $0 |
| Dr. Erik Mittra, M.d., Ph.d, M.D., PH.D | Nuclear Medicine | Portland, OR | $10,275 | $0 |
Ad
Top Products
- PLUVICTO $63.9M
- LUTATHERA $30.3M
Associated Products (5)
- LUTATHERA $50.0M
- LUTATHERA (lutetium LU 177 dotatate) $978,418
- LUTATHERA (lutetium Lu 177 dotatate) $137,684
- NETSPOT (kit for the preparation of gallium Ga 68 dotatate for injection) $96,528
- Lutathera $62,408
Payment Categories
- Food & Beverage $61,613
- Consulting $486,299
- Travel & Lodging $83,417
- Research $2.4M
About Advanced Accelerator Applications
Advanced Accelerator Applications has made $96.8M in payments to 1,188 healthcare providers, recorded across 2,906 transactions in the CMS Open Payments database. In 2024, the company paid $63.9M. The top product by payment volume is PLUVICTO ($63.9M).
Payments were distributed across 64 medical specialties. The top specialty by payment amount is Medical Oncology ($229,968 to 100 doctors).
Payment categories include: Food & Beverage ($61,613), Consulting ($486,299), Research ($2.4M), Travel & Lodging ($83,417).
Advanced Accelerator Applications is associated with 5 products in the CMS Open Payments database, including LUTATHERA, LUTATHERA (lutetium LU 177 dotatate), and LUTATHERA (lutetium Lu 177 dotatate).